Rick Klausner
Founder and CEO @ Lyell Immunopharma
San Francisco Bay Area, United States
Rick Klausner is a Chief Executive Officer at Lyell Immunopharma.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Rick Klausner invests in
Stages Rick Klausner invests in
Countries Rick Klausner invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $30M–$47M
Investment Focus
Industry
- Biotechnology 5 (56%)
- Therapeutics 4 (44%)
- Health Care 3 (33%)
- Life Science 3 (33%)
- Artificial Intelligence 2 (22%)
Stage
- Series A 4 (44%)
- Series B 1 (11%)
- Series C 1 (11%)
- Series E 1 (11%)
- Convertible Note 1 (11%)
Country
- United States 5 (56%)
- Israel 1 (11%)
- United Kingdom 1 (11%)
- The Netherlands 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $126M / Series C / Nov 03, 2025 | ||
| Meatable is a food production company that produces guilt-free meat. Meatable is a company that creates manufactured meat using stem cell technology. By employing pluripotent stem cells, which have the potential to transform any type of cell from muscle to fat without serum, the company's method eliminates the need to remove any tissue from ananimal, allowing consumers to have sustainable food. | $47M / Series A / Mar 23, 2021 | ||
| Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $50M / Series B / Jan 07, 2021 | ||
| Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneersin Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. | $30M / Series A / Sep 30, 2020 | ||
| Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-readyhuman cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation. | $41.5M / Series A / Jun 15, 2020 | ||
| CERo Therapeutics, Inc. is a new cellular immunotherapy company. We have created a hybrid platform that integrates innate and adaptive programs to eliminate disease. | $40M / Series A / Mar 18, 2020 | ||
| Eureka Therapeutics is a biotechnology company that focuses on immunotherapies for the treatment of cancer. The company's platform is a novel T-cell therapy construct that mimics the natural biology of T-cells to fight cancer. It utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancerantigens.Eureka Therapeutics was founded in 2006 and is headquartered in Emeryville, California. | $45M / Series E / Mar 17, 2020 | ||
| Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneersin Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. | $40M / Series A / Feb 06, 2020 | ||
| Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health. | $4.1M / Convertible Note / Jun 01, 2018 |
Co-Investors
About Lyell Immunopharma
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferativecapacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Lyell Immunopharma Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Elizabeth Homans
CEO
|
|||
Heather Turner
Chief Legal Officer
|
|||
Omar Ali
Senior Director of Research
|
|||
Gary Lee
Chief Scientific Officer
|
|||
Scott Boyken
Co-Founder, Co-Director of Protein & Cell Engineering
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Rick Klausner invest in?
Rick Klausner invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Rick Klausner's check size?
Rick Klausner typically joins rounds of $30M–$47M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rick Klausner participates in.
How do I contact Rick Klausner?
Public channels for Rick Klausner include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Rick Klausner last invest?
The most recent investment recorded for Rick Klausner closed in Nov 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
